Bioxcel Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Bioxcel Therapeutics, Inc. holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include BT, IGALMI, and BT BIOXCEL THERAPEUTICS. The owner is based in New Haven, CT.
555 Long Wharf Drive, 12th Floor
New Haven, CT 06516
Showing of trademarks Trademarks
Trademark Classifications
Bioxcel Therapeutics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Bioxcel Therapeutics, Inc. have?
Bioxcel Therapeutics, Inc. has 17 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 12 abandoned.
What trademark classes does Bioxcel Therapeutics, Inc. file in?
Bioxcel Therapeutics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Bioxcel Therapeutics, Inc.'s most well-known trademarks?
Bioxcel Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as BT, IGALMI, and BT BIOXCEL THERAPEUTICS. These are among 4 currently registered trademarks in the portfolio.
What is Bioxcel Therapeutics, Inc.'s trademark registration success rate?
Bioxcel Therapeutics, Inc. has a 25% trademark registration rate, with 4 out of 16 resolved applications resulting in successful registration. Currently, 1 application is pending review.